HK1203980A1 - Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb - Google Patents
Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rbInfo
- Publication number
- HK1203980A1 HK1203980A1 HK15104552.5A HK15104552A HK1203980A1 HK 1203980 A1 HK1203980 A1 HK 1203980A1 HK 15104552 A HK15104552 A HK 15104552A HK 1203980 A1 HK1203980 A1 HK 1203980A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6653808P | 2008-02-21 | 2008-02-21 | |
| US14590109P | 2009-01-20 | 2009-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1203980A1 true HK1203980A1 (en) | 2015-11-06 |
Family
ID=41265206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11106212.6A HK1152053A1 (en) | 2008-02-21 | 2011-06-16 | Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb |
| HK15104552.5A HK1203980A1 (en) | 2008-02-21 | 2015-05-14 | Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11106212.6A HK1152053A1 (en) | 2008-02-21 | 2011-06-16 | Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20110052600A1 (xx) |
| EP (1) | EP2250200A2 (xx) |
| JP (3) | JP2011514335A (xx) |
| KR (1) | KR101240904B1 (xx) |
| CN (2) | CN104151428B (xx) |
| AU (2) | AU2009244878B2 (xx) |
| BR (1) | BRPI0907196B1 (xx) |
| CA (1) | CA2715503C (xx) |
| HK (2) | HK1152053A1 (xx) |
| MX (1) | MX2010009100A (xx) |
| MY (1) | MY184345A (xx) |
| WO (1) | WO2009136976A2 (xx) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| GB0905972D0 (en) * | 2009-04-06 | 2009-05-20 | Medical Res Council | Antibodies against IL-17BR |
| SG10201604093XA (en) | 2010-01-15 | 2016-07-28 | Kirin Amgen Inc | Antibody formulation and therapeutic regimens |
| WO2011123507A1 (en) | 2010-03-30 | 2011-10-06 | Centocor Ortho Biotech Inc. | Humanized il-25 antibodies |
| US8993727B2 (en) * | 2010-09-22 | 2015-03-31 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| CN102188707B (zh) * | 2011-02-25 | 2015-08-05 | 中国医学科学院基础医学研究所 | Il-17抑制剂在制备治疗流感的药物中的用途 |
| WO2013016220A1 (en) * | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| US9834601B2 (en) | 2012-06-12 | 2017-12-05 | Orega Biotech | Antagonists of IL-17 isoforms and their uses |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
| US9858304B2 (en) * | 2014-04-15 | 2018-01-02 | Raytheon Company | Computing cross-correlations for sparse data |
| CN107148283A (zh) * | 2014-10-31 | 2017-09-08 | 豪夫迈·罗氏有限公司 | 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法 |
| US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
| CN106729634A (zh) * | 2017-01-05 | 2017-05-31 | 中国科学院微生物研究所 | 白介素17在抵御流感病毒侵染中的应用 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| KR20230040375A (ko) | 2017-09-22 | 2023-03-22 | 오티토픽 인코퍼레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
| US20240124528A1 (en) * | 2020-12-14 | 2024-04-18 | Academia Sinica | Antagonist of interleukin-17b receptor (il-17rb) and use thereof |
| WO2022155403A1 (en) * | 2021-01-14 | 2022-07-21 | Academia Sinica | Recombinant polypeptides, conjugates comprising the same, and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4373495B2 (ja) * | 1995-03-23 | 2009-11-25 | イミュネックス・コーポレーション | Ｉｌ−１７受容体 |
| US6680057B1 (en) * | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
| US6482923B1 (en) * | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| EP1015488B1 (en) * | 1997-09-17 | 2009-09-09 | Human Genome Sciences, Inc. | Interleukin-17 receptor-like protein |
| US6849719B2 (en) * | 1997-09-17 | 2005-02-01 | Human Genome Sciences, Inc. | Antibody to an IL-17 receptor like protein |
| US20030180255A1 (en) * | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| CA2425506A1 (en) * | 2000-10-18 | 2002-08-01 | Immunex Corporation | Methods for treating rheumatoid arthritis using il-17 antagonists |
| AU2006214384A1 (en) * | 2005-02-14 | 2006-08-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of IL-17F in diagnosis and therapy of airway inflammation |
| JP2009507023A (ja) * | 2005-09-01 | 2009-02-19 | シェーリング コーポレイション | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
| US7833527B2 (en) * | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| WO2008156709A1 (en) * | 2007-06-13 | 2008-12-24 | Amgen Inc. | Il-17 heteromeric receptor complex |
| JP5561689B2 (ja) * | 2007-11-28 | 2014-07-30 | 独立行政法人理化学研究所 | Ｉｌ−１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法 |
-
2009
- 2009-02-20 CA CA2715503A patent/CA2715503C/en active Active
- 2009-02-20 CN CN201410242489.3A patent/CN104151428B/zh active Active
- 2009-02-20 BR BRPI0907196-2A patent/BRPI0907196B1/pt active IP Right Grant
- 2009-02-20 US US12/918,449 patent/US20110052600A1/en not_active Abandoned
- 2009-02-20 EP EP09742963A patent/EP2250200A2/en not_active Withdrawn
- 2009-02-20 MY MYPI2010003877A patent/MY184345A/en unknown
- 2009-02-20 JP JP2010547641A patent/JP2011514335A/ja active Pending
- 2009-02-20 MX MX2010009100A patent/MX2010009100A/es active IP Right Grant
- 2009-02-20 AU AU2009244878A patent/AU2009244878B2/en active Active
- 2009-02-20 KR KR1020107021168A patent/KR101240904B1/ko active IP Right Grant
- 2009-02-20 CN CN200980115731.8A patent/CN102037017B/zh active Active
- 2009-02-20 WO PCT/US2009/001085 patent/WO2009136976A2/en active Application Filing
-
2011
- 2011-06-16 HK HK11106212.6A patent/HK1152053A1/xx unknown
-
2013
- 2013-05-16 AU AU2013205944A patent/AU2013205944A1/en not_active Abandoned
-
2014
- 2014-02-13 JP JP2014025504A patent/JP2014122231A/ja not_active Withdrawn
- 2014-04-28 US US14/263,534 patent/US20140322238A1/en not_active Abandoned
- 2014-06-04 JP JP2014115952A patent/JP5647748B2/ja active Active
-
2015
- 2015-05-14 HK HK15104552.5A patent/HK1203980A1/xx unknown
-
2016
- 2016-01-12 US US14/994,108 patent/US20160208004A1/en not_active Abandoned
- 2016-11-02 US US15/341,870 patent/US20170114140A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014122231A (ja) | 2014-07-03 |
| CA2715503C (en) | 2016-08-09 |
| US20140322238A1 (en) | 2014-10-30 |
| MY184345A (en) | 2021-04-01 |
| MX2010009100A (es) | 2010-12-06 |
| EP2250200A2 (en) | 2010-11-17 |
| KR101240904B1 (ko) | 2013-03-11 |
| CN104151428B (zh) | 2017-07-14 |
| AU2009244878B2 (en) | 2013-06-13 |
| AU2009244878A1 (en) | 2009-11-12 |
| US20160208004A1 (en) | 2016-07-21 |
| CN102037017B (zh) | 2014-07-09 |
| AU2009244878A2 (en) | 2010-10-14 |
| KR20100115380A (ko) | 2010-10-27 |
| WO2009136976A2 (en) | 2009-11-12 |
| JP5647748B2 (ja) | 2015-01-07 |
| CN104151428A (zh) | 2014-11-19 |
| US20110052600A1 (en) | 2011-03-03 |
| BRPI0907196A2 (pt) | 2015-07-14 |
| JP2014185162A (ja) | 2014-10-02 |
| AU2013205944A1 (en) | 2013-06-06 |
| BRPI0907196B1 (pt) | 2021-05-25 |
| CA2715503A1 (en) | 2009-11-12 |
| CN102037017A (zh) | 2011-04-27 |
| HK1152053A1 (en) | 2012-02-17 |
| JP2011514335A (ja) | 2011-05-06 |
| WO2009136976A3 (en) | 2010-04-01 |
| US20170114140A1 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300039I1 (hu) | PSMA-kötõ szerek és alkalmazásaik | |
| HK1203980A1 (en) | Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb | |
| HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
| IL210506A0 (en) | Complement antagonists and uses thereof | |
| HK1196358A1 (en) | Substituted pyridin-2-ones and pyridazin-3-ones -2--3- | |
| HK1183435A1 (en) | Frizzled-binding agents and uses thereof | |
| IL210804A (en) | Benzylidenehydrazides and their uses | |
| ZA201103456B (en) | Leukolectins and uses thereof | |
| EP2291377A4 (en) | IMIDAZOPYRIMIDINONE AND ITS USES | |
| EP2247601A4 (en) | THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF | |
| EP2273266A4 (en) | PARASPORIN-1 RECEPTOR AND USE THEREOF | |
| HK1146065A1 (en) | Nlrr-1 antagonists and uses thereof nlrr-1 | |
| GB0808857D0 (en) | Methdos and uses | |
| HU0800405D0 (en) | Ewnvironment-friendly biocidis and use thereof | |
| GB0711398D0 (en) | Substituted organpolysiloxanes and uses thereof | |
| GB0910620D0 (en) | Agents and uses thereof |